ST Pharm Co.,Ltd.

KOSDAQ 237690.KQ

ST Pharm Co.,Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: 80.34

ST Pharm Co.,Ltd. Price to Earnings Ratio (P/E) is 80.34 on January 14, 2025, a 24.75% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • ST Pharm Co.,Ltd. 52-week high Price to Earnings Ratio (P/E) is 121.31 on September 20, 2024, which is 50.99% above the current Price to Earnings Ratio (P/E).
  • ST Pharm Co.,Ltd. 52-week low Price to Earnings Ratio (P/E) is 62.20 on January 18, 2024, which is -22.57% below the current Price to Earnings Ratio (P/E).
  • ST Pharm Co.,Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 88.16.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
KOSDAQ: 237690.KQ

ST Pharm Co.,Ltd.

CEO Mr. Geun-Jo Im Ph.D.
IPO Date June 23, 2016
Location South Korea
Headquarters MSA Building
Employees 566
Sector Health Care
Industries
Description

ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. In addition, the company offers generic APIs for anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppressant, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medicines, as well as MRI contrast agents. Further, it provides 2nd battery, electronic materials, and polymer catalysts. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is based in Seoul, South Korea.

Similar companies

196170.KQ

ALTEOGEN Inc.

USD 209.72

3.60%

207940.KS

Samsung Biologics Co.,Ltd.

USD 698.37

1.93%

068270.KS

Celltrion, Inc.

USD 125.83

1.12%

006280.KS

Green Cross Corporation

USD 108.37

-2.33%

StockViz Staff

January 15, 2025

Any question? Send us an email